

APR 16 2004

Sheet 1 of 1

FORM PTOL 849
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480140.444C1APPLICATION NO.
09/912,674**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Donal S. Karanewsky et al.

FILING DATE

July 20, 2001

GROUP ART UNIT

~~1646~~

1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>DL</i>	AA	5,585,357	12/17/96	Dolle et al.	514	18	
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF					
	AG					
	AH					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>DL</i>	AI	Brennan, F.M et al., "Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures," <i>Clinical and Experimental Immunology</i> 81: 278-285, 1990.
<i>DL</i>	AJ	Frost, R.A. et al., "Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle," <i>Am. J. Physiol. Regul. Interg. Comp. Physiol.</i> 283: R698-R709, September 2002.
<i>DL</i>	AK	Meyers, K.P. et al., "Effect of Treatment with Interleukin-1 Receptor Antagonist on the Development of Carrageenan-Induced Pleurisy in the Rat," <i>Inflammation</i> 17(2): 121-134, April 1993.
<i>DL</i>	AL	Paris, M.M. et al., "Effect of Interleukin-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor in Animal Models of Infection," <i>The Journal of Infectious Diseases</i> 171(1): 161-169, January 1995.
<i>DL</i>	AM	Read, S.J. et al., "Limiting Neurological Damage After Stroke. A Review of Pharmacological Treatment Options," <i>Drugs & Aging</i> 14(1): 11-39, January 1999.
<i>DL</i>	AN	Rosenbaum and Boney, "Activity of an Interleukin 1 Receptor Antagonist in Rabbit Models of Uveitis," <i>Archives of Ophthalmology</i> 110: 547-549, April 1992.

EXAMINER

David E. Etkin

DATE CONSIDERED

6-30-05

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480140.444C1		APPLICATION NO. 09/912,674	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Donald S. Karanewsky et al.		FILING DATE July 20, 2001	
				GROUP ART UNIT 1646 1654			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>DL</i>	AA	5,656,627	08/12/97	Bemis et al.	514	221	
<i>DL</i>	AB	5,714,484	02/03/98	Zimmerman et al.	514	231.5	
<i>DL</i>	AC	5,919,790	07/06/99	Allen et al.	514	278	
<i>DL</i>	AD	6,242,422 B1	06/05/01	Karanewsky et al.	514	19	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
<i>DL</i>	AE	EP 623 592 B1	06/27/01	EPO			
	AF	EP 623 606 B1	01/07/98	EPO			
	AG	EP 644 197 B1	09/09/98	EPO			
	AH	EP 761 680 A2	03/12/97	EPO			
	AI	GB 2,292,149	02/14/96	UK			
	AJ	WO 93/09135	05/13/93	WIPO			
	AK	WO 95/05192	02/23/95	WIPO			
	AL	WO 96/30395	10/03/96	WIPO			
	AM	WO 97/22618	06/26/97	WIPO			
	AN	WO 99/47545	09/23/99	WIPO			
<i>DL</i>	AO	WO 99/66945	12/29/99	WIPO			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>DL</i>	AP	Dolle et al., "Pyridazinodiazepines as a High-Affinity, P2-P3 Peptidomimetic Class of Interleukin-1 β -Converting Enzyme Inhibitor," <i>J. Medicinal Chemistry</i> 40(13):1941-1945, June 20, 1997.					
<i>DL</i>	AQ	Semple et al., "Peptidomimetic Aminomethylene Ketone Inhibitors of Interleukin-1 β -Converting Enzyme (ICE)," <i>Bioorganic & Medicinal Chemistry Letters</i> 8(8):959-964, April 21, 1998.					
EXAMINER <i>David Lukan</i>				DATE CONSIDERED 6-30-05			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

 RECEIVED
 FEB 14 2002
 1600/2900